Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

HER2+ breast cancer (BC) is an aggressive subtype genetically and biologically heterogeneous. We evaluate the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in 154 HER2+ BCs patients who received trastuzumab-based neoadjuvant chemother...

Full description

Saved in:

Bibliographic Details
Published in:	Scientific reports Vol. 13; no. 1; pp. 12869 - 14
Main Authors:	Orrù, Sandra, Pascariello, Emanuele, Pes, Barbara, Rallo, Vincenzo, Barbara, Raffaele, Muntoni, Marta, Notari, Francesca, Fancello, Gianfranco, Mocci, Cristina, Muroni, Maria Rosaria, Cossu-Rocca, Paolo, Angius, Andrea, De Miglio, Maria Rosaria
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 08.08.2023 Nature Publishing Group Nature Portfolio
Subjects:	631/67 692/53 Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer therapies Chemotherapy Decision making ErbB-2 protein Female Gene expression Humanities and Social Sciences Humans Lymph nodes Lymphatic system Lymphocytes, Tumor-Infiltrating Machine learning Medical prognosis Metastases Microenvironments Monoclonal antibodies multidisciplinary Neoadjuvant Therapy Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Science Science (multidisciplinary) Trastuzumab Trastuzumab - therapeutic use Treatment Outcome Tumor Microenvironment
ISSN:	2045-2322, 2045-2322
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!